贝伐单抗联合替莫唑胺治疗复发性脑胶质瘤的初步研究

目的　观察贝伐单抗联合替莫唑胺治疗复发性脑胶质瘤患者的近期疗效和安全性。方法　２０１０年２月至２０１０年９月共１８例复发性脑胶质瘤患者给予贝伐单抗联合替莫唑胺方案治疗，具体方案为：替莫唑胺１５０～２００ｍｇ／（ｍ２·ｄ），口服，ｄ１～ｄ５，２８ｄ为１个周期；贝伐单抗５ｍｇ／ｋｇ，每１４ｄ静脉滴注１次。至少接受２个周期化疗后评价疗效和不良反应，并记录６个月无进展生存率和６个月总生存率。结果　１８例患者获ＰＲ６例（３３.３％），ＳＤ９例（５０.０％），ＰＤ３例（１６.７％）。６个月无进展生存率和总生存率分别为６６.７％（１２／１８）和７７.８％（１４／１８）。主要不良反应包括骨髓抑制和胃肠道反应，均为１～２级。结论　贝伐单抗联合替莫唑胺治疗复发性脑胶质瘤近期疗效较好，不良反应可耐受，远期疗效尚需进一步观察。

Primary study of bevacizumab combined with temozolomide for recurrent glioma

Objective To evaluate the side effect and efficacy of bevacizumab combined with temozolomide for recurrent glioma prospectively.Methods From February 2010 to September 2010,18 cases of recurrent glioma were enrolled in this study.All the patients received temozolomide(150-200mg/m2,d1-d5,oral administration,28 days was a cycle) and bevacizumab(5mg/kg,iv,once for every 14 days).Efficacy and side effects were evaluated after two cycles' chemotherapy.Six months' progression-free survival rate and overall surviv...